Bioavailability Study Comparing Modified Release To Immediate Release Apixaban Tablets In Healthy Volunteers

A Randomized, Open-Label, Single Dose, Four Way Cross-Over Bioavailability Study Comparing Three Modified Release Formulations Of Apixaban Tablets To Apixaban Immediate Release Tablets In Healthy Volunteers

To estimate the pharmacokinetics of apixaban when administered as three different modified release formulation tablets relative to that when apixaban is administered as an immediate release tablet

Inclusion Criteria:

• Healthy male or female patients
• Body Mass Index (BMI) of 17.5 to 30.5 kg/m2

Exclusion Criteria:

• Any condition possibly affecting drug absorption
• History or evidence of abnormal bleeding or clotting disorder